Satralizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 168 publications

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 06, 2026

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 17, 2025

What is in the Neuromuscular Junction Literature?

What is in the Neuromuscular Junction Literature?

Journal: Journal of clinical neuromuscular disease

Published: December 03, 2025

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 06, 2025

Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review.

Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review.

Journal: Modern rheumatology case reports

Published: September 29, 2025

Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.

Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.

Journal: Expert opinion on emerging drugs

Published: September 23, 2025

Decrease in Urinary Tract Infections Following Switch From Anti-Interleukin-6 Monoclonal Antibody to Ravulizumab in a Patient With Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report.

Decrease in Urinary Tract Infections Following Switch From Anti-Interleukin-6 Monoclonal Antibody to Ravulizumab in a Patient With Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report.

Journal: Cureus

Published: September 21, 2025

Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review.

Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review.

Journal: Multiple sclerosis and related disorders

Published: September 16, 2025

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG-IgG Dual Seropositive: A Case Report.

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG-IgG Dual Seropositive: A Case Report.

Journal: Annals of clinical and translational neurology

Published: September 03, 2025

Neuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan.

Neuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: September 03, 2025

Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.

Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.

Journal: Annals of clinical and translational neurology

Published: August 22, 2025

Safe Childbirth in a Patient with Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.

Safe Childbirth in a Patient with Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.

Journal: Internal medicine (Tokyo, Japan)

Published: August 13, 2025

Showing 1-12 of 168

Last Updated: 02/24/2026